Mankind Pharma
Drug Manufacturers - Specialty & Generic · MANKIND
Large CapHealthcareHigh Growth
Rajeev Juneja
Vice Chairman and Managing Director · Pragmatic
Company DNA
Founder-Centric
About
Mankind Pharma is a Large Cap company in the Healthcare sector, listed on NSE as MANKIND. With a market cap of ₹89K Cr and revenue of ₹12K Cr, it is currently in the High Growth phase. Known for its Founder-Centric culture and Fast-Follower approach to innovation, the company operates at a Startup-Speed pace. Highly aggressive sales culture heavily influenced by the visionary and hands-on leadership of Rajeev Juneja. Its strategic mandate: To sustain its aggressive domestic market share gains and integrate recent acquisitions, the firm needs a leader focused on operational efficiency and channel depth.
FAQ
What kind of company is Mankind Pharma?
Mankind Pharma is a Large Cap Healthcare company (MANKIND) in the High Growth phase with a market cap of ₹89K Cr. It is classified as Founder-Centric in culture.
What is Mankind Pharma's culture and work environment like?
Mankind Pharma has a Founder-Centric culture with Fast-Follower innovation DNA and a Startup-Speed pace of execution. Employee brand: Demanding Machine. Customer relationship style: Mass-Consumer. Highly aggressive sales culture heavily influenced by the visionary and hands-on leadership of Rajeev Juneja.
Who leads Mankind Pharma?
Mankind Pharma is led by Rajeev Juneja (Vice Chairman and Managing Director), a Pragmatic leader with 41 years of experience.
What are Mankind Pharma's financials?
Mankind Pharma reported revenue of ₹12K Cr in FY25 with a 5-year revenue CAGR of 16.2%. Operating margin: 20.6%. Market cap: ₹89K Cr.
Culture & Strategy
CultureFounder-Centric
InnovationFast-Follower
PaceStartup-Speed
PurposePurpose-Blended
CustomerMass-Consumer
EmployeeDemanding Machine
BrandValue-Champion
LifecycleHigh Growth
Highly aggressive sales culture heavily influenced by the visionary and hands-on leadership of Rajeev Juneja.
Mandate
To sustain its aggressive domestic market share gains and integrate recent acquisitions, the firm needs a leader focused on operational efficiency and channel depth.
To sustain its aggressive domestic market share gains and integrate recent acquisitions, the firm needs a leader focused on operational efficiency and channel depth.
Financials
Revenue FY25₹12K Cr
PAT FY25₹2K Cr
Rev CAGR 5Y16.2%
OPM20.6%
NPM16.3%
ROE13.9%
ROCE11.4%
P/E49.5
Fwd P/E35.7
P/B5.8
D/E53.9
Mkt Cap₹89K Cr
Promoter75.3%
Institutional19%
Similar Culture
Could You Lead Mankind Pharma?
Take the Genome Benchmark →